Description

Neurocrine Biosciences: CRENESSITY Is Just Getting Started—From Endocrinologists to Primary Care, a Much Bigger Opportunity Emerges!

Neurocrine Biosciences recently reported its fourth quarter and fiscal year 2025 financial results, showcasing strong performance driven by its products INGREZZA and CRENESSITY. The company recorded total sales exceeding $2.8 billion, reflecting a notable 22% year-over-year growth. INGREZZA contributed over $2.5 billion in revenue, marking a 9% increase from the previous year, primarily fueled by double-digit volume growth. However, pricing concessions aimed at securing long-term formulary access partially offset this growth. Moving into 2026, Neurocrine anticipates continued growth for INGREZZA, projecting sales between $2.7 billion and $2.8 billion. CRENESSITY, introduced to the market following its 2024 FDA approval, has shown strong initial performance, with net sales exceeding $300 million by the end of 2025. The drug has successfully penetrated about 10% of the classic and general congenital adrenal hyperplasia (CAH) patient population within a year.